|
Piperazine
» Piperazine contains not less than 98.0 percent and not more than 101.0 percent of C4H10N2, calculated on the anhydrous basis.
Packaging and storage
Preserve in tight containers, protected from light.
Color of solution
Dissolve 10.0 g in water, and dilute with water to 50.0 mL: the solution has no more color than a standard solution prepared by adding 2.0 mL of ferric chloride CS to water and diluting with water to 50.0 mL, when compared in matched color-comparison tubes.
Change to read:
Identification
B:
In the test for Chromatographic purity, the principal spot in the chromatogram of Test solution 2, observed after spraying with the ninhydrin solutions, corresponds in RF value, color, and size to that in the chromatogram of Standard solution 1.
Water, Method I
Delete the following:
Add the following:
Solvent
Prepare a mixture of 13.5 N ammonium hydroxide and dehydrated alcohol (3:2).
Standard solution 1
Prepare a solution of USP Piperazine RS in Solvent containing 10 mg per mL.
Standard solution 2
Prepare a solution of ethylenediamine in Solvent containing 0.25 mg per mL.
Standard solution 3
Prepare a solution of triethylenediamine in Solvent containing 0.25 mg per mL.
Resolution solution
Prepare a solution in Solvent containing 0.25 mg of triethylenediamine and 10 mg of USP Piperazine RS per mL.
Test solution 1
Prepare a solution of Piperazine in Solvent containing 100 mg per mL.
Test solution 2
Mix 1 mL of Test solution 1 and 9 mL of Solvent.
Procedure
Apply separate 5-µL portions of Standard solution 1, Standard solution 2, Standard solution 3, Resolution solution, Test solution 1, and Test solution 2 to a suitable thin-layer chromatographic plate (see Chromatography
Assay
Weigh accurately about 150 mg of Piperazine, and dissolve in 75 mL of glacial acetic acid. Titrate potentiometrically with 0.1 N perchloric acid VS, using a silver-glass electrode system. As the endpoint is approached, warm the solution to 60
Auxiliary Information
Please check for your question in the FAQs before contacting USP.
USP32NF27 Page 3313
Pharmacopeial Forum: Volume No. 34(1) Page 105
|